Differential proteome analysis of serum proteins associated with the development of type 2 diabetes mellitus in the KK-Ay mouse model using the iTRAQ technique

Journal of Proteomics

Volumn 84, Issue , 2013, Pages 40-51

  Takahashi, Eri ^a,b   Okumura, Akinori ^a   Unoki Kubota, Hiroyuki ^a   Hirano, Hisashi ^b   Kasuga, Masato ^a   Kaburagi, Yasushi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Multiple reaction monitoring; Quantitative mass spectrometry; Serum proteome; Type 2 diabetes mellitus

Indexed keywords

CELL PROTEIN; CYSTEINE; PROTEOME; SERINE; SERPINA3K PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATION EXCHANGE; CELL MEMBRANE PERMEABILITY; CLADISTICS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; ENDOTHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METHODOLOGY; MOUSE; MULTIPLE REACTION MONITORING ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; RETINAL MICROVASCULAR ENDOTHELIAL CELL; SENSITIVITY AND SPECIFICITY; TRANSENDOTHELIAL PERMEABILITY; WILD TYPE;

ANIMALS; BLOOD PROTEINS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, MUTANT STRAINS; PROTEOME; PROTEOMICS;

ANIMALIA; MUS;

EID: 84876711606     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.03.014     Document Type: Article

References (37)

1. Korc M. Diabetes mellitus in the era of proteomics. Mol Cell Proteomics 2003, 2:399-404.
2. Gerich J.E. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998, 19:491-503.
3. Klein R., Klein B.E.K., Moss S.E., Cruickshanks K.J. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998, 105:1801-1815.
4. Horikawa Y., Yamasaki T., Nakajima H., Shingu R., Yoshiuchi I., Miyagawa J., et al. Identification of a novel variant in the phosphoenolpyruvate carboxykinase gene promoter in Japanese patients with type 2 diabetes. Horm Metab Res 2003, 35:308-312.
5. Vendrell J., Fernandez-Real J.M., Gutierrez C., Zamora A., Simon I., Bardaji A., et al. A polymorphism in the promoter of the tumor necrosis factor-α gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis 2003, 167:257-264.
6. Lindgren C.M., Widen E., Tuomi T., Li H., Almgren P., Kanninen T., et al. Contribution of known and unknown susceptibility genes to early-onset diabetes in Scandinavia: evidence for heterogeneity. Diabetes 2002, 51:1609-1617.
7. Rao A.A., Sridhar G.R., Das U.N. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 2007, 69:1272-1276.
8. Rao A.A., Sridhar G.R., Srinivas B., Das U.N. Bioinformatics analysis of functional protein sequences reveals a role for brain-derived neurotrophic factor in obesity and type 2 diabetes mellitus. Med Hypotheses 2008, 70:424-429.
9. On Y.K., Park H.K., Hyon M.S., Jeon E.S. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007, 71:868-873.
10. Zhang R., Barker L., Pinchev D., Marshall J., Rasamoelisolo M., Smith C., et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004, 4:244-256.
11. Dayal B., Ertel N.H. ProteinChip technology: a new and facile method for the identification and measurement of high-density lipoproteins apoA-I and apoA-II and their glycosylated products in patients with diabetes and cardiovascular disease. J Proteome Res 2002, 1:375-380.
12. Sundsten T., Eberhardson M., Goransson M., Bergsten P. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci 2006, 4:22.
13. y allele on quantitative regulation. Mamm Genome 1998, 9:506-510.
14. Unoki-Kubota H., Yamagishi S., Takeuchi M., Bujo H., Saito Y. Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett 2010, 17:1177-1181.
15. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
16. Okumura A., Ohta H., Inoue Y., Enami I. Identification of functional domains of the extrinsic 12kDa protein in red algal PSII by limited proteolysis and directed mutagenesis. Plant Cell Physiol 2001, 42:1331-1337.
17. Giaever I., Keese C.R. Micromotion of mammalian cells measured electrically. Proc Natl Acad Sci U S A 1991, 88:7896-7900.
18. Nishimura M. Breeding of mice strains for diabetes mellitus. Exp Anim 1969, 18:147-157.
19. Hatcher H.C., Ma J.X., Chao J., Chao L., Ottlecz A. Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 1997, 38:658-664.
20. Gao G., Shao C., Zhang S.X., Dudley A., Fant J., Ma J.-X. Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia 2003, 46:689-698.
21. Klein R., Klein B.E.K., Moss S.E., Cruickshanks K.J. The Wisconsin epidemiologic study of diabetic retinopathy. Opthalmology 1995, 102:7-16.
22. Kaur P., Rizk N.M., Ibrahim S., Younes N., Uppal A., Dennis K., et al. iTRAQ-based quantitative protein expression profiling and MRM verification of markers in type 2 diabetes. J Proteome Res 2012, 11:5527-5539.
23. Overgaard A.J., Thingholm T.E., Larsen M.R., Tarnow L., Rossing P., McGuire J.N., et al. Quantitative iTRAQ-based proteomic identification of candidate biomarkers for diabetic nephropathy in plasma of type 1 diabetic patients. Clin Proteomics 2010, 6:105-114.
24. García-Ramírez M., Canals F., Hernández C., Colomé N., Ferrer C., Carrasco E., et al. Proteomic analysis of human vitreous fluid by fluorescence based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 2007, 50:1294-1303.
25. Klöting N., Graham T.E., Berndt J., Kralisch S., Kovacs P., Wason C.J., et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 2007, 6:79-87.
26. Fernández-Real J.M., Moreno J.M., Ricart W. Circulating retinol-binding protein-4 concentration might reflect insulin resistance-associated iron overload. Diabetes 2008, 57:1918-1925.
27. Raila J., Henze A., Spranger J., Möhlig M., Pfeiffer A.F., Schweigert F.J. Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in type 2 diabetic patients. Kidney Int 2007, 72:505-511.
28. Chao J., Chai K.X., Chen L.M., Xiong W., Chao S., Woodley-Miller C., et al. Tissue kallikrein-binding protein is a SERPIN. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 1990, 265:16394-16401.
29. Chao J., Tillman D.M., Wang M.Y., Margolius H.S., Chao L. Identification of a new tissue-kallikrein-binding protein. Biochem J 1986, 239:325-331.
30. Gettins P.G. SERPIN structure, mechanism, and function. Chem Rev 2002, 102:4751-4803.
31. Zhang B., Hu Y., Ma J.X. Anti-inflammatory and antioxidant effects of SERPINA3K in the retina. Invest Ophthalmol Vis Sci 2009, 50:3943-3952.
32. Zhang B., Abreu J.G., Zhou K., Chen Y., Hu Y., Zhou T., et al. Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family. Proc Natl Acad Sci U S A 2010, 107:6900-6905.
33. Kwak M.K., Wakabayashi N., Itoh K., Motohashi H., Yamamoto M., Kensler T.W. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway: identification of novel gene clusters for cell survival. J Biol Chem 2003, 278:8135-8145.
34. Ishii T., Itoh K., Ruiz E., Leake D.S., Unoki H., Yamamoto M., et al. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ Res 2004, 94:609-616.
35. Xu J., Kulkarni S.R., Donepudi A.C., More V.R., Slitt A.L. Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. Diabetes 2012, 61:3208-3218.
36. American Diabetes Association Implications of the diabetes control and complications trial. American Diabetes Association. Diabetes 1993, 42:1555-1558.
37. Ohkubo K., Ogata S., Misumi Y., Takami N., Ikehara Y. Molecular cloning and characterization of rat contrapsin-like protease inhibitor and related proteins. J Biochem 1991, 109:243-250.